Certuity LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 319.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,933 shares of the company’s stock after acquiring an additional 7,564 shares during the period. Certuity LLC’s holdings in Eli Lilly and Company were worth $5,790,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently made changes to their positions in LLY. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares in the last quarter. Morgan Stanley increased its position in Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after buying an additional 83,915 shares in the last quarter. Northern Trust Corp increased its position in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after buying an additional 355,317 shares in the last quarter. International Assets Investment Management LLC increased its position in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Eli Lilly and Company by 2.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock valued at $2,382,339,000 after buying an additional 88,016 shares in the last quarter. 82.53% of the stock is owned by institutional investors.
Insider Transactions at Eli Lilly and Company
In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Trading Up 6.0 %
NYSE LLY traded up $44.10 during trading on Tuesday, hitting $781.30. 5,419,168 shares of the company’s stock traded hands, compared to its average volume of 3,044,902. The stock has a fifty day moving average of $760.89 and a two-hundred day moving average of $668.00. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12-month low of $392.26 and a 12-month high of $800.78. The firm has a market cap of $742.36 billion, a P/E ratio of 134.43, a PEG ratio of 1.60 and a beta of 0.34.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the business posted $2.09 earnings per share. The company’s revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- How to Calculate Retirement Income: MarketBeat’s Calculator
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What Makes a Stock a Good Dividend Stock?
- Hilton Demonstrates Asset Light is Right for Investors
- Upcoming IPO Stock Lockup Period, Explained
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.